Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies

Fluocinolone acetonide (FAc) intravitreal implant (Iluvien(®)) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non–infectious posterior uveitis, and as an off-label treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Mushtaq, Yusuf, Mushtaq, Maryam M, Gatzioufas, Zisis, Ripa, Matteo, Motta, Lorenzo, Panos, Georgios D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069638/
https://www.ncbi.nlm.nih.gov/pubmed/37020801
http://dx.doi.org/10.2147/DDDT.S403259
Descripción
Sumario:Fluocinolone acetonide (FAc) intravitreal implant (Iluvien(®)) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non–infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non-biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders.

Ejemplares similares